Max Healthcare Institute Limited reported a strong fourth quarter for FY26, with gross revenue reaching ₹2,664 crore, a 10% year-on-year growth. The company achieved an operating EBITDA of ₹682 crore and a quarterly profit after tax of ₹387 crore. The network expansion continues with significant brownfield additions across major facilities, and the company has successfully expanded its footprint through the acquisition of Kalinga Hospital Ltd in Bhubaneswar.
Financial Highlights
For the quarter ended March 31, 2026, Max Healthcare delivered robust results, maintaining its momentum with its 22nd consecutive quarter of year-on-year growth. The network gross revenue stood at ₹2,664 crore, reflecting a 10% increase compared to the same period last year. Operating EBITDA for the network rose to ₹682 crore, an 8% YoY growth, while the quarterly profit after tax (PAT) reached ₹387 crore, up 3% YoY.
Operational Expansion and Growth
The company has made significant strides in augmenting its healthcare infrastructure. Approximately 20% additional brownfield capacity has been commissioned in the last six months. Key developments include the commissioning of a 400-bed brownfield tower at Max Smart Super Speciality Hospital and the full operationalization of a 160-bed tower at MSSH, Mohali. Furthermore, 116 beds are now operational at the Nanavati-Max brownfield project, with the remaining balance expected to be functional within the next three months.
Strategic Acquisitions and Future Pipeline
In a major strategic move, Max Healthcare consummated the acquisition of a 58.28% controlling stake in Kalinga Hospital Ltd. on May 18, 2026, adding a 250-bed facility in Bhubaneswar to its portfolio. Looking ahead, the company’s board has approved a ~₹1,400 crore investment for a new 712-bed greenfield hospital at Shaheed Path, Lucknow. This new facility, spanning 5 acres, is slated for commissioning by FY30 to address the rising demand for quality healthcare in Uttar Pradesh.
Clinical and Research Excellence
Max Healthcare continues to lead in complex clinical procedures, having performed over 4,458 liver transplants, 5,748 kidney transplants, and 2,248 bone marrow transplants to date. During Q4 FY26, the network published 160 articles in high-impact medical journals and maintains 115 active clinical trials, reinforcing its commitment to cutting-edge medical research and academic rigor.
Source: BSE
